{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:23:28Z","timestamp":1790396608868,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n There is no international consensus on defining vitiligo severity or relapse. Current measures (such as body surface area) quantify depigmentation but do not fully capture the broader clinical and psychosocial effects of the disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop internationally agreed-upon definitions and criteria for vitiligo severity and relapse as part of the International Consensus on Definition of Severity and Relapse in Vitiligo study.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n This global, mixed-methods consensus study used a multistep approach, including comprehensive literature review, qualitative study, 2 rounds of electronic Delphi surveys, and a final consensus meeting. To ensure adequate diversity and inclusivity and to capture a broad range of experiences, perspectives, social contexts, and representation, a recruitment framework (encompassing variation in age, sex, and skin phototypes) was predefined.<\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n In total, 91 people from 5 continents expressed interest in participating. Experts (dermatologists, trialists, methodologists, nurses, psychologists, journal editors, and researchers) and people with vitiligo from diverse ethnic backgrounds and skin phototypes took part. During the first electronic Delphi survey round, 85 people participated and 81 participated in round 2 (response rate of 95% in each survey round). Consensus was reached that even though measurement of body surface area remains a necessary and adequate starting point for assessing vitiligo severity, this measure alone is insufficient to capture disease burden. The final consensus meeting included 44 participants (response rate of 54%). Twelve criteria for upgrading severity were recommended, encompassing both clinical aspects of vitiligo and its psychosocial effects. The major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress, stigmatization, lack of self-acceptance, and overall burden. The minor criteria for vitiligo include darker skin tones, younger age, involvement of scalp\/facial hair, increased risk of sunburn, impact on career or school, and perceived loss of personal or cultural identity. No consensus was reached on the extent of pigment loss. Relapse was defined as loss of pigmentation in previously repigmented lesions (repigmentation had occurred either spontaneously or with treatment).<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n This global, mixed-methods consensus study established internationally agreed-upon severity criteria for vitiligo. This consensus aims to bridge the gap between physician assessment and patient experience; improve the relevance and consistency of the severity classification in clinical care, research, and regulatory frameworks; and help close the remaining gaps in the diagnosis and classification of vitiligo.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.0294","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:49Z","timestamp":1774452649000},"page":"515","source":"Crossref","is-referenced-by-count":5,"title":["Definition of Severity and Relapse for Vitiligo"],"prefix":"10.1001","volume":"162","author":[{"given":"Viktoria","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"Vitiligo Clinical and Research Centre for Adult and Paediatric Patients, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, England"},{"name":"Walsall Manor Hospital, Walsall Healthcare NHS Trust, Walsall, England"},{"name":"College of Medicine and Health, University of Birmingham, Birmingham, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"},{"name":"Innovative Dermatology, Plano, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Taylor","sequence":"additional","affiliation":[{"name":"Vitiligo International Patient Organizations Committee, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Meurant","sequence":"additional","affiliation":[{"name":"Vitiligo International Patient Organizations Committee, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Andrology, and Venereology, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jeong","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00efla","family":"Benzekri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mohammed V University, Ibn Sina University Hospital, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wolkerstorfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Public Health Institute\/Infection and Immunology Institute, Amsterdam University Medical Centers, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihong F.","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rush","sequence":"additional","affiliation":[{"name":"Vitiligo Support Group, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nice University Hospital, Nice, France"},{"name":"C3M, INSERM U1065, University of Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chan Medical School, University of Massachusetts, Worcester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Huggins","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Schneider","sequence":"additional","affiliation":[{"name":"Vitiligo Society, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Kolios","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"},{"name":"Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"School of Medicine, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia M.","family":"Esmat","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Cairo University, Giza, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Murray Learning Centre, Birmingham, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameeta","family":"Retzer","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Murray Learning Centre, Birmingham, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Dermatology and Pediatric Dermatology, National Reference Centre for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"},{"name":"University Bordeaux, CNRS, ImmunoConcept, UMR 5164, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Angeliki","family":"Gkini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Barts Health NHS Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Barts Health NHS Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thompson","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board and School of Psychology, University of Cardiff, Cardiff, England"},{"name":"British Psychological Society, Leicester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Palo Alto Foundation Medical Group, Sunnyvale, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Cruz Rivera","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Murray Learning Centre, Birmingham, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny C.","family":"Kpenou","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics, IMRB\u2013Paris-Est Cr\u00e9teil University, INSERM U955, Cr\u00e9teil, France"},{"name":"Public Health Doctoral Network, School of Public Health, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics, IMRB\u2013Paris-Est Cr\u00e9teil University, INSERM U955, Cr\u00e9teil, France"},{"name":"Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique-H\u00f4pitaux de Paris, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"INTERCEPT Study Group and the Global Vitiligo Atlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Elbuluk","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Leone","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mar","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Ho Oh","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ferguson","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oiso","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noufal","family":"Raboobee","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanja","family":"VanGeel","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Alomar","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Thng Tien Guan","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lan","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Ghia","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bertolotti","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Alberti","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Kumarasinghe","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahy","family":"El-Basyouni","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gan","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Huang","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Cesar","family":"Silva de Castro","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Hee Han","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Cy","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Miller","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnawaz","family":"Towheed","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Creasor","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerith","family":"Waters","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Money","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Nightingale","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Tait","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Simon","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mackay","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Eccles","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Reade","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Kerr","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Berry","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Reynolds","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Wright","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Tipping","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Kumar","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hilsdon","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Burton","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Whincup","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Muhammad","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Scott","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tolentino","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Roufs","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hubbard","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hall","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing","family":"Adamu","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Archibald","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Blanks","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslean","family":"Temple","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dechandal","sequence":"additional","affiliation":[{"name":"for the INTERCEPT Study Group and the Global Vitiligo Atlas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dcs260001r1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.annder.2022.11.008","article-title":"Burden of visible [face and hands] skin diseases: results from a large international survey.","volume":"150","author":"Richard","year":"2023","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"dcs260001r2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjd.19704","article-title":"Putting the burden of skin diseases on the global map.","volume":"184","author":"Flohr","year":"2021","journal-title":"Br J Dermatol"},{"issue":"9988","key":"dcs260001r3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo.","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"dcs260001r4","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study.","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"issue":"10","key":"dcs260001r5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study.","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dcs260001r6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","article-title":"The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis.","volume":"178","author":"Osinubi","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"dcs260001r7","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.591","article-title":"The mental health associations of vitiligo: UK population-based cohort study.","volume":"8","author":"Thompson","year":"2022","journal-title":"BJPsych Open"},{"issue":"6","key":"dcs260001r8","first-page":"385","article-title":"Vitiligo patients experience barriers in accessing care.","volume":"98","author":"Chen","year":"2016","journal-title":"Cutis"},{"issue":"9","key":"dcs260001r9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13555-023-00983-3","article-title":"Real-world treatment patterns in patients with vitiligo in the United States.","volume":"13","author":"Rosmarin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"dcs260001r10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1365-2133.2005.06456.x","article-title":"Effect of vitiligo on self-reported health-related quality of life.","volume":"152","author":"Ongenae","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"dcs260001r12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial.","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"dcs260001r13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study.","volume":"93","author":"Pandya","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"dcs260001r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"7","key":"dcs260001r15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s13555-025-01397-z","article-title":"Efficacy and safety of JAK inhibitors in the management of vitiligo: a systematic review and meta-analysis.","volume":"15","author":"Mohammed","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"dcs260001r16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamadermatol.2023.5869","article-title":"The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity.","volume":"160","author":"Moussa","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"10","key":"dcs260001r17","doi-asserted-by":"publisher","DOI":"10.1111\/srt.70276","article-title":"Vitiligo: ruxolitinib and other oral treatment options beyond ruxolitinib.","volume":"31","author":"Ghani","year":"2025","journal-title":"Skin Res Technol"},{"issue":"11","key":"dcs260001r18","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: a new treatment for vitiligo.","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"dcs260001r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15321819.2024.2412528","article-title":"Emerging therapies and innovations in vitiligo management: a comprehensive review.","volume":"46","author":"Bhange","year":"2025","journal-title":"J Immunoassay Immunochem"},{"issue":"1","key":"dcs260001r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi.","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"issue":"7","key":"dcs260001r22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: A narrative review.","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"dcs260001r23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"dcs260001r24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/bjd\/ljac074","article-title":"Has the core outcome (domain) set for vitiligo been implemented? an updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials.","volume":"188","author":"Eleftheriadou","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10","key":"dcs260001r25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.36849\/JDD.8049","article-title":"A review of the vitiligo literature to standardize expression of disease severity.","volume":"23","author":"Renert-Yuval","year":"2024","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"dcs260001r26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021.","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"issue":"11","key":"dcs260001r27","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 2: specific treatment recommendations.","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"dcs260001r28","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm.","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"dcs260001r29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/1346-8138.12099","article-title":"Guidelines for the diagnosis and treatment of vitiligo in Japan.","volume":"40","author":"Oiso","year":"2013","journal-title":"J Dermatol"},{"issue":"3","key":"dcs260001r30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ddg.14713","article-title":"S1 guideline: diagnosis and therapy of vitiligo.","volume":"20","author":"B\u00f6hm","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"dcs260001r31","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3823","article-title":"Patients\u2019 perception of vitiligo severity.","volume":"101","author":"van Geel","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"dcs260001r32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12955-016-0490-y","article-title":"Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL).","volume":"14","author":"Hedayat","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"dcs260001r33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2133.2008.08678.x","article-title":"Identification of categories at risk for high quality of life impairment in patients with vitiligo.","volume":"159","author":"Sampogna","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"dcs260001r34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bjd.18950","article-title":"Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).","volume":"183","author":"van Geel","year":"2020","journal-title":"Br J Dermatol"},{"key":"dcs260001r35","doi-asserted-by":"publisher","first-page":"l1476","DOI":"10.1136\/bmj.l1476","article-title":"Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis.","volume":"365","author":"Levis","year":"2019","journal-title":"BMJ"},{"key":"dcs260001r36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","article-title":"Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7).","volume":"265","author":"Toussaint","year":"2020","journal-title":"J Affect Disord"},{"issue":"2","key":"dcs260001r37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jdv.18641","article-title":"Patient Unique Stigmatization Holistic Tool in Dermatology (PUSH-D): development and validation of a dermatology-specific stigmatization assessment tool.","volume":"37","author":"Ezzedine","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"dcs260001r38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/bjd\/ljae020","article-title":"Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic Tool in Dermatology (PUSH-D) score.","volume":"190","author":"Fakih","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"dcs260001r39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1037\/0022-3514.89.4.623","article-title":"Simultaneous administration of the Rosenberg Self-Esteem Scale in 53 nations: exploring the universal and culture-specific features of global self-esteem.","volume":"89","author":"Schmitt","year":"2005","journal-title":"J Pers Soc Psychol"},{"key":"dcs260001r40","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.41120","article-title":"A systematic review of 207 studies describing validation aspects of the Dermatology Life Quality Index.","volume":"104","author":"Vyas","year":"2024","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"dcs260001r41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/JID.2015.398","article-title":"The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool.","volume":"136","author":"Salzes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"dcs260001r11","unstructured":"World Health Organization. Skin diseases as a global public health priority. Published May 27, 2025. Accessed February 17, 2026. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA78\/A78_R15-en.pdf"},{"key":"dcs260001r19","unstructured":"National Institute for Health and Care Excellence. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. Published August 13, 2025. Accessed February 17, 2026. https:\/\/www.nice.org.uk\/guidance\/ta1088\/informationforpublic"},{"key":"dcs260001r42","unstructured":"British Association of Dermatologists. Ritlecitinib for alopecia areata: professional guidance supplementary to NICE TA958. Published July 2024. Accessed February 17, 2026. https:\/\/cdn.bad.org.uk\/uploads\/2024\/07\/01005430\/Ritlecitinib-for-alopecia-areata-supplementary-guidance-26.06.24.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2846494\/jamadermatology_eleftheriadou_2026_cs_260001_1787314376.65008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:19Z","timestamp":1787756419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2846494"}},"subtitle":["An International Consensus Statement"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0294","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}